"Antibody drug conjugates: the long road from concepts to reality"

Antibody drug conjugates: the long road from concepts to reality”

Jan Pinkas, Ph.D.
Immunogen, Inc.
Wed, 3/25/2015 - 4:00pm

221 Integrated Sciences Building

Jan Pinkas is a graduate of the University of Massachusetts Molecular and Cellular Biology Graduate Program. During his dissertation research with Joseph Jerry’s lab group, he focused on regulation of the p53 tumor suppressor pathway by MDM2. Jan was a postdoctoral fellow with Philip Leder at Harvard. He has worked extensively in development of novel cancer therapies with pharmaceutical companies. He has also led the effort to develop maytansinoid derivatives, small molecule drugs, at ImmunoGen and collaborating with Genentech to create a first in its class conjugate with anti-EGFR antibodies. Jan will present not only the exciting data supporting this newly approved drug (Kadcyla™), but the long road to FDA approval.

Notes: 

Refreshments at 3:45pm